TD Cowen Has Lowered Expectations for Quanterix (NASDAQ:QTRX) Stock Price

Key Points

• TD Cowen cut its price target on Quanterix from $7 to $4 and kept a "hold" rating; the $4 target matches the analyst consensus and implies roughly a 47% upside from the current share price.
• Shares of QTRX dropped about 17.3% to $2.72 on heavy volume (3.43M vs. average 830K), trading near the 12‑month low and well below the 50‑day ($4.17) and 200‑day ($5.62) moving averages.
• Company fundamentals remain challenged: Q1 EPS was -$0.37 (beats est.), revenue missed at $35.9M, margins and ROE are negative, full‑year EPS is expected around -0.97, and market cap is about $128M.

Quanterix (NASDAQ:QTRX - Get Free Report) had its target price lowered by equities researchers at TD Cowen from $7.00 to $4.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a "hold" rating on the stock. TD Cowen's price objective points to a potential upside of 47.06% from the stock's current price.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Quanterix from a "hold" rating to a "sell" rating in a research note on Saturday, April 18th. Canaccord Genuity Group reduced their price target on Quanterix from $8.00 to $4.00 and set a "hold" rating for the company in a research note on Monday, April 20th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Quanterix in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Reduce" and an average target price of $4.00.

Quanterix Stock Down 17.3%

Shares of NASDAQ QTRX traded down $0.57 during midday trading on Thursday, hitting $2.72. 3,433,141 shares of the company's stock were exchanged, compared to its average volume of 830,315. Quanterix has a 12 month low of $2.56 and a 12 month high of $8.77. The company's 50 day moving average price is $4.17 and its 200 day moving average price is $5.62. The firm has a market capitalization of $128.00 million, a PE ratio of -1.08 and a beta of 1.15.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.14. The business had revenue of $35.90 million during the quarter, compared to analysts' expectations of $36.84 million. Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%. On average, equities research analysts anticipate that Quanterix will post -0.97 EPS for the current year.

Institutional Trading of Quanterix

Several large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC acquired a new position in Quanterix in the fourth quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in Quanterix during the fourth quarter worth about $27,000. Quarry LP increased its holdings in Quanterix by 277,300.0% in the 3rd quarter. Quarry LP now owns 5,548 shares of the company's stock valued at $30,000 after buying an additional 5,546 shares during the period. R Squared Ltd bought a new position in Quanterix in the 3rd quarter valued at about $64,000. Finally, AXQ Capital LP acquired a new position in shares of Quanterix in the 4th quarter valued at approximately $70,000. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.